PREVIEW
OF YOUR NEWS WIDGETHepatitis news and hepatitis widget
Tuesday, November 11, 2008 ( change date )
Roche, InterMune And Pharmasset Announce Initiation Of INFORM-1, The First Dual Combination Clinical Trial With Oral Antivirals In Hepatitis C
Pharmasset, Inc. (Nasdaq: VRUS), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: ITMN) announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in Australia and New Zealand) is the first to investigate the combination of two oral antiviral molecules in the absence of interferon.
Medicalnewstoday.com Tuesday, November 11, 2008
INSTALL YOUR WIDGET